

Cancer Immunotherapy TRCCC-CIM Symposium July 10-11, 2017 Havana, Cuba



Affiliate member



CIM

Centro de Inmunología
Molecular

TRCCC Member Institutions



JOHNS HOPKINS
UNIVERSITY



And Also



ADVANCING SCIENCE. SERVING SOCIETY

Meeting Sponsors

The logo for immudex features the word "immudex" in a blue, lowercase, sans-serif font. A small orange square is positioned above the first letter 'i'.

The logo for CTL Europe GmbH consists of the letters "CTL." in a large, bold, black, sans-serif font. The dots are colored: red for the first, blue for the second, and black for the third. Below this, the words "Europe GmbH" are written in a smaller, black, sans-serif font. A horizontal line connects the end of "CTL." to the start of "Europe". At the bottom right, there is a decorative graphic of several red and blue circles of varying sizes.

Additional Support



TRCCC-CIM Meeting, Havana, Cuba.

July 10 and 11, 2017

Monday 10 July, 2017

9.00-9.15 a.m. Welcome by Dr. Agustin Lage, Director of CIM.

9.15-9.30a.m Dr. Kalet Leon Monzon, Director of Research and Development, Center of Molecular Immunology (CIM): A brief overview of CIM.

9.30-9.45 a.m. Welcome by Dr. Yasmin Thanavala on behalf of TRCCC

9.45-10.15a.m. Dr. Sergio Pastrana, Executive Director and Secretary of Foreign Affairs of the Academy of Sciences of Cuba: Highlights on the history of scientific links, the most recent of those, and the role of Academies in international cooperation.

10.15 -10.45 a.m. Dr. Marga Gual Soler, Project Director AAAS Center for Science Diplomacy: AAAS and the Cuban Academy of Sciences: building scientific bridges between the United States and Cuba.

10.45-11.00 a.m. Dr. Mahlet Mesfin, Deputy Director, AAAS Center for Science Diplomacy: Reflections on US-Cuba science and technology cooperation during the Obama Administration

11- 11.15 a.m. Coffee Break

Scientific Session 1: Chaired by Dr. Kelvin Lee

11.15-12.00 p.m. Dr. Tania Crombet: CIM immunotherapies in the clinical setting: an update on Nimotuzumab and CIMAvax.

12-12.45 p.m. Dr. Yasmin Thanavala: Immunosuppressive pathways in HCC patients.

12.45-1.30 p.m. Dr. Wei-Zen Wei: Rational Design of HER2 Vaccine and Genetic Regulation of Vaccine Response.

1.30-2.45 p.m. Lunch hosted by CIM

Scientific Session 2 Chaired by Drs. Tays Hernandez and Circe Mesa

2.45-3.30 p.m. Dr. Belinda Sánchez: Cancer vaccines based on HER family oncogenes.

3.30-4.00 p.m. Dr. Stephen Haley: Why take a chance you are missing something? MHC Dextramers for the detection of tumor-specific T cells.

4.00-4.45 p.m. Dr. Zaima Mazorra: Nimotuzumab activates the immune system and induces specific anti-EGFR T cells.

Dinner 7p.m. Hosted by TRCCC

Tuesday July 11, 2017

Scientific Session 3: Chaired by Dr. Yasmin Thanavala

9.00-9.45 a.m. Dr. Elizabeth Repasky: Adrenergic signaling at the crossroads of stress, immunosuppression and cancer.

9.45-10.30 a.m. Dr. Circe Mesa: Ganglioside containing nanoparticles: a novel approach to reprogram tumor-altered myeloid compartment and overcome immunosuppression.

10.30-11.00a.m. Dr. Paul von Hoegen: Unique features of ImmunoSpot assays for monitoring T cell and B cell immunity to tumors.

11.00-11.45a.m. Dr. Jonathan Bramson: A novel chimeric receptor for engineered T cells.

11.45-12.30 p.m. Dr. Tania Carmente: How far can we go manipulating IL-2- IL-2R interactions?

Lunch 12.30 p.m.-1.45.p.m. Hosted by CIM

Scientific Session 4: Chaired by Dr. Kalet Leon Monzon

1.45-2.30 p.m. Dr. John Frelinger: Activatable fusion proteins to enhance immune responses to tumors.

2.30-3.15 p.m. Dr. Luis Enrique Fernández: Glycovaxgm3: a non-personalized neoantigen-based therapeutic vaccine for breast cancer patients.

3.15-4.00p.m. Denise Dorvignit Pedroso, MSc: Targeting the tumor-specific antigen GM3(Neu5Gc) ganglioside with a cytotoxic monoclonal antibody.

Summary of meeting and future goals: Dr. Wei-Zen Wei and Dr. Kelvin Lee

Dinner 7 p.m. Hosted by AAAS and RPCI